Jonathan P C Hasselmann1, Hawra Karim1, Anna J Khalaj1, Subir Ghosh2, Seema K Tiwari-Woodruff3. 1. Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA 92521, USA. 2. Department of Statistics, UCR-CNAS, Riverside, CA 92521, USA. 3. Division of Biomedical Sciences, UCR School of Medicine, Riverside, CA 92521, USA; Department of Neuroscience, UCR School of Medicine, Riverside, CA 92521, USA; Center for Glial-Neuronal Interactions, UCR School of Medicine, CA 92506, USA. Electronic address: seema.tiwari-woodruff@medsch.ucr.edu.
Abstract
BACKGROUND: While many groups use experimental autoimmune encephalomyelitis (EAE) as a model to uncover therapeutic targets and understand the pathology underlying multiple sclerosis (MS), EAE protocol variability introduces discrepancies in central nervous system (CNS) pathogenesis and clinical disease, limiting the comparability between studies and slowing much-needed translational research. OPTIMIZED METHOD: Here we describe a detailed, reliable protocol for chronic EAE induction in C57BL/6 mice utilizing two injections of myelin oligodendrocyte glycoprotein (35-55) peptide mixed with complete Freund's adjuvant and paired with pertussis toxin. RESULTS: The active MOG35-55-EAE protocol presented here induces ascending paralysis in 80-100% of immunized mice. We observe: (1) consistent T cell immune activation, (2) robust CNS infiltration by peripheral immune cells, and (3) perivascular demyelinating lesions concurrent with axon damage in the spinal cord and various brain regions, including the optic nerve, cortex, hippocampus, internal capsule, and cerebellum. COMPARISON WITH EXISTING METHOD(S): Lack of detailed protocols, combined with variability between laboratories, make EAE results difficult to compare and hinder the use of this model for therapeutic development. We provide the most detailed active MOG35-55-EAE protocol to date. With this protocol, we observe high disease incidence and a consistent, reliable disease course. The resulting pathology is MS-like and includes optic neuritis, perivascular mononuclear infiltration, CNS axon demyelination, and axon damage in both infiltrating lesions and otherwise normal-appearing white matter. CONCLUSIONS: By providing a detailed active MOG35-55-EAE protocol that yields consistent and robust pathology, we aim to foster comparability between pre-clinical studies and facilitate the discovery of MS therapeutics.
BACKGROUND: While many groups use experimental autoimmune encephalomyelitis (EAE) as a model to uncover therapeutic targets and understand the pathology underlying multiple sclerosis (MS), EAE protocol variability introduces discrepancies in central nervous system (CNS) pathogenesis and clinical disease, limiting the comparability between studies and slowing much-needed translational research. OPTIMIZED METHOD: Here we describe a detailed, reliable protocol for chronic EAE induction in C57BL/6 mice utilizing two injections of myelin oligodendrocyte glycoprotein (35-55) peptide mixed with complete Freund's adjuvant and paired with pertussis toxin. RESULTS: The active MOG35-55-EAE protocol presented here induces ascending paralysis in 80-100% of immunized mice. We observe: (1) consistent T cell immune activation, (2) robust CNS infiltration by peripheral immune cells, and (3) perivascular demyelinating lesions concurrent with axon damage in the spinal cord and various brain regions, including the optic nerve, cortex, hippocampus, internal capsule, and cerebellum. COMPARISON WITH EXISTING METHOD(S): Lack of detailed protocols, combined with variability between laboratories, make EAE results difficult to compare and hinder the use of this model for therapeutic development. We provide the most detailed active MOG35-55-EAE protocol to date. With this protocol, we observe high disease incidence and a consistent, reliable disease course. The resulting pathology is MS-like and includes optic neuritis, perivascular mononuclear infiltration, CNS axon demyelination, and axon damage in both infiltrating lesions and otherwise normal-appearing white matter. CONCLUSIONS: By providing a detailed active MOG35-55-EAE protocol that yields consistent and robust pathology, we aim to foster comparability between pre-clinical studies and facilitate the discovery of MS therapeutics.
Authors: J Ochoa-Repáraz; D W Mielcarz; Y Wang; S Begum-Haque; S Dasgupta; D L Kasper; L H Kasper Journal: Mucosal Immunol Date: 2010-06-09 Impact factor: 7.313
Authors: André M Deslauriers; Amir Afkhami-Goli; Amber M Paul; Rakesh K Bhat; Shaona Acharjee; Kristofor K Ellestad; Farshid Noorbakhsh; Marek Michalak; Christopher Power Journal: J Immunol Date: 2011-09-30 Impact factor: 5.422
Authors: Louise M Topping; Laura Romero-Castillo; Vilma Urbonaviciute; Hans Bolinsson; Felix I Clanchy; Rikard Holmdahl; B Thomas Bäckström; Richard O Williams Journal: Front Immunol Date: 2022-06-13 Impact factor: 8.786
Authors: Hawra Karim; Sung Hoon Kim; Andrew S Lapato; Norio Yasui; John A Katzenellenbogen; Seema K Tiwari-Woodruff Journal: Proc Natl Acad Sci U S A Date: 2018-05-29 Impact factor: 11.205
Authors: Hawra Karim; Sung Hoon Kim; Kelli Lauderdale; Andrew S Lapato; Kelley Atkinson; Norio Yasui; Hana Yamate-Morgan; Maria Sekyi; John A Katzenellenbogen; Seema K Tiwari-Woodruff Journal: Sci Rep Date: 2019-01-24 Impact factor: 4.379